back to
back to

Program: Sunday (27.10.2024)

08:00 – 09:30

Room: Großer Saal

Scientific Session Pediatric and Adolescent Treatment Concepts

  • Jonathan Friedberg
  • Christine Mauz-Körholz
  • 08:00–08:20

    Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

    • Sharon Castellino
  • 08:20–08:40

    Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

    • Christine Mauz-Körholz
  • 08:40–09:00

    Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

    • Jamie Flerlage
    • Kara Kelly
  • 09:00–09:10

    EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

    • Dieter Körholz
  • 09:10–09:20

    Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

    • Sharon Castellino
  • 09:20–09:30

    Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

    • Kara Kelly

10:00 – 11:30

Room: Großer Saal

Scientific Session Biology & Microenvironment

  • Sirpa Leppä
  • Margaret Shipp
  • 10:00–10:25

    Pathogenesis of HL

    • Ralf Küppers
  • 10:25–10:50

    Multimodal characterization of cHL

    • Christian Steidl
  • 10:50–11:00

    Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

    • Kristiina Karihtala
  • 11:00–11:10

    Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

    • Michel Heger
  • 11:10–11:20

    Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

    • Michael Binkley
  • 11:20–11:30

    Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

    • Tomohiro Aoki

12:00 – 13:30

Room: Großer Saal

Satellite Symposium (by MSD Sharp & Dohme GmbH) New concepts for the treatment of B-cell lymphomas

  • Peter Borchmann
  • 12:00–12:30

    B-cell lymphoma pathology – illustrated for non- pathologists

    • Wolfram Klapper
  • 12:30–13:00

    Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

    • Peter Borchmann
  • 13:00–13:30

    Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

    • Sascha Dietrich

14:00 – 15:30

Room: Großer Saal

Scientific Session Older Patients

  • Paul J. Bröckelmann
  • Andrew Evens
  • 14:00–14:25

    Implementing Frailty Assessment for Treatment Guidance in HL

    • Sarah Rutherford
  • 14:25–14:50

    Optimal Use of Targeted Agents to Address Unmet Need in Older HL

    • Graham Collins
  • 14:50–15:00

    A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

    • Kjersti Lia
  • 15:00–15:10

    Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

    • Aisling Barrett
  • 15:10–15:20

    Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

    • Justin Ferdinandus
  • 15:20–15:30

    Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

    • Sarah Rutherford

16:00 – 17:30

Room: Großer Saal

Satellite Symposium (by Takeda Pharmaceuticals USA, Inc.) Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma

  • John Radford
  • 16:00–16:05

    Welcome and introduction

  • 16:05–16:15

    Spotlight on ECHELON-1: 7-year survival data

    • John Radford
  • 16:15–16:45

    Real-world insights: frontline treatment of stages III & IV cHL

    • Chiara Rusconi
  • 16:45–17:00

    Q&A

  • 17:00–17:25

    cHL in the real-world: a case study approach

    • Carolina Valeria Mahuad
    • John Radford

18:00 – 19:30

Room: Großer Saal

Scientific Session Advanced Stages

  • Alex Herrera
  • Josée Zijlstra
  • 18:00–18:25

    Individualized treatment de-escalation improves overall outcomes

    • Peter Borchmann
  • 18:25–18:50

    Immune-chemotherapy overcomes the need for individualization

    • Jonathan Friedberg
  • 18:50–19:00

    2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

    • Alex Herrera
  • 19:00–19:10

    Development and application of a validated MRD assay in Hodgkin Lymphoma

    • Julia Mattlener
  • 19:10–19:20

    EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

    • Martin Hutchings
  • 19:20–19:30

    Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

    • Justin Ferdinandus

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.